G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

Under the terms of the J&J deal, Isomorphic will be responsible for in silico predictions and design, while the US group will ...

University of Southern California-led researchers have discovered the structural details of a brain receptor called GPR6, which could lead to new treatments for Parkinson's disease. GPR6 is an orphan ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...